Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | KMT2A rearrange |
Gene Variant Detail | |
Relevant Treatment Approaches |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03114865 | Phase Ib/II | Blinatumomab + Dexamethasone | A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | Active, not recruiting | USA | 0 |
NCT03513484 | Phase I | Azacitidine + Nintedanib | Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT03674411 | Phase II | Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | Active, not recruiting | USA | 0 |
NCT05918913 | Expanded access | Revumenib | Expanded Access Program for SNDX-5613 | Available | USA | 0 |
NCT01338987 | Phase II | Tacrolimus Busulfan Methotrexate Leuprolide Cyclophosphamide Fludarabine | Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation | Completed | USA | 0 |
NCT02141828 | Phase I | Pinometostat | A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene | Completed | USA | CAN | 0 |
NCT02828358 | Phase II | Cytarabine + Hydrocortisone + Leucovorin + Mercaptopurine + Pegaspargase Cyclophosphamide + Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Azacitidine Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Pegaspargase + Thioguanine + Vincristine sulfate liposome Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Pegaspargase + Prednisolone + Vincristine Sulfate Mercaptopurine + Methotrexate Cyclophosphamide + Cytarabine + Thioguanine | Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement | Completed | USA | CAN | AUS | 1 |
NCT05326516 | Phase I | Revumenib | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | Completed | USA | CAN | 0 |
NCT06769490 | Phase I | Quizartinib + Ziftomenib | Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia | Not yet recruiting | USA | 0 |
NCT06852222 | Phase III | Azacitidine + Bleximenib + Venetoclax Azacitidine + Venetoclax | A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML) (cAMeLot-2) | Not yet recruiting | ISR | 0 |
NCT06930352 | Phase II | Ziftomenib | Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy | Not yet recruiting | USA | 0 |
NCT03613532 | Phase I | Azacitidine + Venetoclax Busulfan + Fludarabine + Venetoclax Decitabine and Cedazuridine | Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN | Recruiting | USA | 0 |
NCT03826992 | Phase I | CPX-351 + Venetoclax | Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia | Recruiting | USA | 0 |
NCT04065399 | Phase Ib/II | Revumenib | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101) | Recruiting | USA | NLD | LTU | ITA | ISR | FRA | ESP | DEU | CAN | AUS | 1 |
NCT04307576 | Phase III | Imatinib Blinatumomab Inotuzumab ozogamicin | A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | Recruiting | SWE | NOR | NLD | LTU | ISL | IRL | GBR | FRA | FIN | EST | DNK | DEU | BEL | 1 |
NCT04659616 | Phase I | Cytarabine + Pemigatinib Cytarabine + Daunorubicin + Pemigatinib | Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT05327894 | Phase III | Blinatumomab | Interfant-21 Treatment Protocol for Infants Under 1 Year with KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia (Interfant-21) | Recruiting | SWE | SVK | NOR | NLD | LTU | ITA | IRL | HUN | FRA | FIN | ESP | DNK | DEU | CZE | BEL | AUT | AUS | ARG | 4 |
NCT05507827 | Phase I | CD19-22.BB.z CAR T cells | Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL | Recruiting | USA | 0 |
NCT05554393 | Phase II | Cytarabine + Daunorubicin Cytarabine + Daunorubicin + Venetoclax Azacitidine + Venetoclax | Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | Recruiting | USA | CAN | 1 |
NCT05735184 | Phase I | Azacitidine + Venetoclax + Ziftomenib Cytarabine + Daunorubicin + Ziftomenib Venetoclax + Ziftomenib | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML | Recruiting | USA | 0 |
NCT05748171 | Phase II | Asparaginase + Dexamethasone + Mitoxantrone + Vincristine Sulfate Inotuzumab ozogamicin | A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL | Recruiting | SWE | SVK | POL | NOR | NLD | ITA | ISR | HUN | FRA | FIN | ESP | DNK | DEU | CZE | CHE | BEL | AUT | 0 |
NCT05761171 | Phase II | Cytarabine + Fludarabine Pegaspargase + Prednisone + Vincristine Sulfate Calaspargase pegol-mknl + Prednisone + Vincristine Sulfate Revumenib Cytarabine + Hydrocortisone + Methotrexate Pegaspargase + Prednisolone + Vincristine Sulfate Calaspargase pegol-mknl + Prednisolone + Vincristine Sulfate | A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia | Recruiting | USA | CAN | 0 |
NCT05848687 | Phase Ib/II | Bortezomib Dexamethasone Blinatumomab Vorinostat Mercaptopurine Pegaspargase Methotrexate Ziftomenib Mitoxantrone | TINI 2: Total Therapy for Infants with Acute Lymphoblastic Leukemia II | Recruiting | USA | CAN | 0 |
NCT05886049 | Phase I | Cytarabine + Daunorubicin + Revumenib | Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene | Recruiting | USA | 0 |
NCT05918692 | Phase I | BMF-500 | A Phase 1, Study of BMF-500 in Adults With Acute Leukemia | Recruiting | USA | 0 |
NCT06001788 | Phase I | Gilteritinib + Ziftomenib Cytarabine + Ziftomenib Cytarabine + Filgrastim + Fludarabine + Idarubicin + Ziftomenib | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Recruiting | USA | ITA | ESP | 0 |
NCT06152809 | Phase I | Aldesleukin + CIML-NK cells + Venetoclax | CIML NK Cells With Venetoclax for AML | Recruiting | USA | 0 |
NCT06173518 | Phase I | Obecabtagene autoleucel | A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) | Recruiting | USA | GBR | ESP | 0 |
NCT06177067 | Phase I | Cytarabine + Hydrocortisone + Methotrexate Azacitidine + Revumenib + Venetoclax | Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT06222580 | Phase I | Gilteritinib + Revumenib | SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation | Recruiting | USA | 0 |
NCT06226571 | Phase I | Cytarabine + Idarubicin + Revumenib Revumenib Cytarabine + Daunorubicin + Revumenib Cytarabine | A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias | Recruiting | USA | GBR | ESP | AUS | 0 |
NCT06229912 | Phase II | Revumenib | A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes | Recruiting | USA | 0 |
NCT06284486 | Phase II | Revumenib + Venetoclax | A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib | Recruiting | USA | 0 |
NCT06287229 | Phase Ib/II | Brexucabtagene autoleucel Blinatumomab + Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Sulfate Blinatumomab + Cyclophosphamide + Dexamethasone + Inotuzumab ozogamicin + Vincristine Sulfate | Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab | Recruiting | USA | 0 |
NCT06313437 | Phase I | Cytarabine + Daunorubicin + Midostaurin + Revumenib Cytarabine + Midostaurin + Revumenib | Revumenib in Combination With 7+3 + Midostaurin in AML | Recruiting | USA | 0 |
NCT06376162 | Phase I | Ziftomenib Cytarabine + Fludarabine + Ziftomenib | Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia | Recruiting | USA | NLD | FRA | ESP | CAN | AUT | 0 |
NCT06397027 | Phase I | Azacitidine + Venetoclax + Ziftomenib | A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias | Recruiting | USA | 0 |
NCT06440135 | Phase I | Ziftomenib | Ziftomenib Maintenance Post Allo-HCT | Recruiting | USA | 0 |
NCT06448013 | Phase I | Gemtuzumab ozogamicin + Venetoclax + Ziftomenib | A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT06575296 | Phase I | Revumenib | Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant | Recruiting | USA | 0 |
NCT01028716 | Phase II | Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Terminated | USA | 0 |
NCT02419755 | Phase II | Cytarabine Mercaptopurine Methotrexate Pegaspargase Vorinostat Doxorubicin Bortezomib Dexamethasone Mitoxantrone Prednisone | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies | Terminated | USA | 0 |
NCT03724084 | Phase Ib/II | Cytarabine + Daunorubicin + Pinometostat | Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement | Terminated | USA | 0 |
NCT04326439 | Phase II | Cytarabine + Etoposide Cytarabine + Etoposide + Sorafenib Asparaginase Erwinia chrysanthemi + Cytarabine + Sorafenib Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin + Sorafenib Cytarabine + Mitoxantrone + Sorafenib Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin Asparaginase Erwinia chrysanthemi + Cytarabine Cytarabine + Mitoxantrone | AflacLL1901 (CHOA-AML) | Terminated | USA | 0 |
NCT04752163 | Phase Ib/II | Cyclophosphamide + Cytarabine + Dexamethasone + DS-1594b + Filgrastim + Mesna + Methotrexate + Vincristine Sulfate DS-1594b + Prednisone + Vincristine Sulfate DS-1594b Azacitidine + DS-1594b + Venetoclax Cytarabine + DS-1594b + Filgrastim + Leucovorin + Methotrexate Cytarabine + DS-1594b + Filgrastim + Leucovorin + Methotrexate + Rituximab | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | Terminated | USA | 0 |
CKB CORE allows for only a limited number of monthly page views for un-registered users. However, registration is free and allows for unlimited browsing of the CKB CORE content.
You have reached the monthly page view limit. For continued free access to CKB CORE, please register below: